


AMENDMENT TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method for inhibiting a mitotic kinesin Eg5 which comprises administering an effective amount of a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof. A mitotic kinesin-Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient:



wherein:

R¹ represents

a hydrogen atom,

a substituted or unsubstituted lower alkyl,

a substituted or unsubstituted lower alkenyl,

a substituted or unsubstituted lower alkynyl,

a substituted or unsubstituted cycloalkyl,

a substituted or unsubstituted aryl,

or a substituted or unsubstituted heterocyclic group;

R² represents

- a hydrogen atom,
- a substituted or unsubstituted lower alkyl,
- a substituted or unsubstituted lower alkenyl,
- a substituted or unsubstituted lower alkynyl,
- a substituted or unsubstituted cycloalkyl,
- a substituted or unsubstituted aryl, ~~or~~
- a substituted or unsubstituted heterocyclic group,
- C(=W)R⁶, {wherein W represents an oxygen atom or a sulfur atom, and R⁶

represents

- a hydrogen atom,
- a substituted or unsubstituted lower alkyl,
- a substituted or unsubstituted lower alkenyl,
- a substituted or unsubstituted lower alkynyl,
- a substituted or unsubstituted cycloalkyl,
- a substituted or unsubstituted aryl, or
- a substituted or unsubstituted heterocyclic group,
- NR⁷R⁸, {wherein R⁷ and R⁸ are the same or different and

- each represents a hydrogen atom,
- a substituted or unsubstituted lower alkyl,
- a substituted or unsubstituted lower alkenyl,
- a substituted or unsubstituted lower alkynyl,
- a substituted or unsubstituted cycloalkyl,

a substituted or unsubstituted aryl, or
a substituted or unsubstituted heterocyclic
group,
or R⁷ and R⁸ are combined together with the adjacent nitrogen
atom to form a substituted or unsubstituted heterocyclic
group},

-OR⁹, (wherein R⁹ represents a substituted or unsubstituted lower alkyl,
a substituted or unsubstituted lower alkenyl,
a substituted or unsubstituted lower alkynyl,
a substituted or unsubstituted cycloalkyl,
a substituted or unsubstituted aryl, or
a substituted or unsubstituted heterocyclic group), or
-SR¹⁰, (wherein R¹⁰ has the same meaning as that of the aforementioned
R⁹),

-NR¹¹R¹², {wherein R¹¹ and R¹² are the same or different and each represents
a hydrogen atom,
a substituted or unsubstituted lower alkyl,
a substituted or unsubstituted lower alkenyl,
a substituted or unsubstituted lower alkynyl,
a substituted or unsubstituted cycloalkyl,
a substituted or unsubstituted aryl,
a substituted or unsubstituted heterocyclic group,
-C(=O)R¹³, {wherein R¹³ represents

a hydrogen atom,
a substituted or unsubstituted lower alkyl,
a substituted or unsubstituted lower alkenyl,
a substituted or unsubstituted lower alkynyl,
a substituted or unsubstituted cycloalkyl,
a substituted or unsubstituted aryl,
a substituted or unsubstituted heterocyclic group,
 $\text{-NR}^{14}\text{R}^{15}$, (wherein R^{14} and R^{15} are the same or different and each
represents a hydrogen atom,
a substituted or unsubstituted lower alkyl,
a substituted or unsubstituted lower alkenyl,
a substituted or unsubstituted lower alkynyl,
a substituted or unsubstituted cycloalkyl,
a substituted or unsubstituted aryl, or
a substituted or unsubstituted heterocyclic group, or
 R^{14} and R^{15} are combined together with the adjacent
nitrogen atom to form a substituted or unsubstituted
heterocyclic group),
 -OR^{16} , (wherein R^{16} has the same meaning as that of the
aforementioned R^9), or
 -SR^{17} , (wherein R^{17} has the same meaning as that of the
aforementioned R^9), or

R^{11} and R^{12} are combined together with the adjacent nitrogen atom to form
a substituted or unsubstituted heterocyclic group}, or

$-SO_2R^{18}$, {wherein R^{18} represents

a substituted or unsubstituted lower alkyl,

a substituted or unsubstituted lower alkenyl,

a substituted or unsubstituted lower alkynyl,

a substituted or unsubstituted cycloalkyl,

a substituted or unsubstituted aryl, or

a substituted or unsubstituted heterocyclic group}, or

R^1 and R^2 are combined together with the adjacent nitrogen atom to form a
substituted or unsubstituted heterocyclic group,

R^3 represents

a hydrogen atom, or

$-C(=Z)R^{19}$, {wherein Z represents an oxygen atom or a sulfur atom, and R^{19}
represents a hydrogen atom,

a substituted or unsubstituted lower alkyl,

a substituted or unsubstituted lower alkenyl,

a substituted or unsubstituted lower alkynyl,

a substituted or unsubstituted cycloalkyl,

a substituted or unsubstituted aryl,

a substituted or unsubstituted heterocyclic group, or

$-NR^{20}R^{21}$, {wherein R^{20} and R^{21} are the same or different and each represents
a hydrogen atom,

a substituted or unsubstituted lower alkyl,
a substituted or unsubstituted lower alkenyl,
a substituted or unsubstituted lower alkynyl,
a substituted or unsubstituted cycloalkyl,
a substituted or unsubstituted aryl, or
a substituted or unsubstituted heterocyclic group, or
 R^{20} and R^{21} are combined together with the adjacent nitrogen atom to form
a substituted or unsubstituted heterocyclic group},

-OR²² (wherein R²² represents

a substituted or unsubstituted lower alkyl,
a substituted or unsubstituted lower alkenyl,
a substituted or unsubstituted lower alkynyl,
a substituted or unsubstituted cycloalkyl,
a substituted or unsubstituted aryl, or
a substituted or unsubstituted heterocyclic group}, or

-SR²³, (wherein R²³ has the same meaning as that of the aforementioned R²²),

R⁴ represents

a hydrogen atom,
a substituted or unsubstituted lower alkyl,
a substituted or unsubstituted lower alkenyl,
a substituted or unsubstituted lower alkynyl,
a substituted or unsubstituted cycloalkyl,
a substituted or unsubstituted aryl, or

a substituted or unsubstituted heterocyclic group, and

R^5 represents

a substituted or unsubstituted lower alkyl,

a substituted or unsubstituted lower alkenyl,

a substituted or unsubstituted lower alkynyl,

a substituted or unsubstituted cycloalkyl,

a substituted or unsubstituted aryl, or

a substituted or unsubstituted heterocyclic group, or

R^4 and R^5 are combined together to represent $-(CR^{25A}R^{25B})_{m1}Q(CR^{25C}R^{25D})_{m2}$,

wherein

Q represents a single bond, or

a substituted or unsubstituted phenylene or cycloalkylene,

$m1$ and $m2$ are the same or different and each represents an integer of

from 0 to 4, with the proviso that $m1$ and $m2$ are not 0 at the same

time,

R^{25A} , R^{25B} , R^{25C} and R^{25D} are the same or different and each represents

a hydrogen atom,

a halogen,

a substituted or unsubstituted lower alkyl,

$-OR^{26}$ wherein R^{26} represents

a hydrogen atom,

a substituted or unsubstituted lower alkyl,

a substituted or unsubstituted lower alkenyl,

a substituted or unsubstituted lower alkynyl,

a substituted or unsubstituted cycloalkyl,

a substituted or unsubstituted aryl,

a substituted or unsubstituted heterocyclic group,

$-\text{CONR}^{27}\text{R}^{28}$, (wherein R^{27} and R^{28} are the same or

different and each represents

a hydrogen atom,

a substituted or unsubstituted lower alkyl,

a substituted or unsubstituted lower alkenyl,

a substituted or unsubstituted lower alkynyl,

a substituted or unsubstituted cycloalkyl,

a substituted or unsubstituted aryl, or

a substituted or unsubstituted heterocyclic group, or

R^{27} and R^{28} are combined together with the adjacent

nitrogen atom to form a substituted or

unsubstituted heterocyclic group),

$-\text{SO}_2\text{NR}^{29}\text{R}^{30}$, (wherein R^{29} and R^{30} have the same

meanings as those of the aforementioned R^{27} and

R^{28} , respectively), or

$-\text{COR}^{31}$, (wherein R^{31} represents

a hydrogen atom,

a substituted or unsubstituted lower alkyl,

a substituted or unsubstituted lower alkenyl,

a substituted or unsubstituted lower alkynyl,
a substituted or unsubstituted cycloalkyl,
a substituted or unsubstituted aryl, or
a substituted or unsubstituted heterocyclic group}},
-NR³²R³³, {wherein R³² and R³³ are the same or different and each

represents

a hydrogen atom,
a substituted or unsubstituted lower alkyl,
a substituted or unsubstituted lower alkenyl,
a substituted or unsubstituted lower alkynyl,
a substituted or unsubstituted cycloalkyl,
a substituted or unsubstituted aryl,
a substituted or unsubstituted heterocyclic group,
-COR³⁴, {wherein R³⁴ represents

a hydrogen atom,
a substituted or unsubstituted lower alkyl,
a substituted or unsubstituted lower alkenyl,
a substituted or unsubstituted lower alkynyl,
a substituted or unsubstituted cycloalkyl,
a substituted or unsubstituted aryl,
a substituted or unsubstituted heterocyclic group,
a substituted or unsubstituted lower alkoxy,
a substituted or unsubstituted aryloxy, amino,

\underline{a} substituted or unsubstituted lower alkylamino,
 \underline{a} substituted or unsubstituted di-(lower alkyl)amino,
 or \underline{a} substituted or unsubstituted arylamino), or
 $-\text{SO}_2\text{R}^{35}$ (wherein R^{35} represents
 \underline{a} substituted or unsubstituted lower alkyl,
 \underline{a} substituted or unsubstituted lower alkenyl,
 \underline{a} substituted or unsubstituted lower alkynyl,
 \underline{a} substituted or unsubstituted cycloalkyl,
 \underline{a} substituted or unsubstituted aryl, or
 a substituted or unsubstituted heterocyclic group}),
 or $-\text{COOR}^{36}$ (wherein R^{36} represents
 a hydrogen atom,
 \underline{a} substituted or unsubstituted lower alkyl,
 \underline{a} substituted or unsubstituted lower alkenyl,
 \underline{a} substituted or unsubstituted lower alkynyl,
 \underline{a} substituted or unsubstituted cycloalkyl,
 \underline{a} substituted or unsubstituted aryl, or
 a substituted or unsubstituted heterocyclic group), or
 $\text{R}^{25\text{A}}$ and $\text{R}^{25\text{B}}$, or $\text{R}^{25\text{C}}$ and $\text{R}^{25\text{D}}$ are combined together to represent
 an oxygen atom, and
 when m_1 or m_2 is an integer of 2 or above, any of $\text{R}^{25\text{A}}$, $\text{R}^{25\text{B}}$, $\text{R}^{25\text{C}}$
 and $\text{R}^{25\text{D}}$ may be the same or different, and any two of $\text{R}^{25\text{A}}$,

R^{25B} , R^{25C} and R^{25D} which are bound to the adjacent two carbon atoms may be combined to form a bond} >.

2. (Currently Amended) The method ~~The mitotic kinesin Eg5 inhibitor~~ according to claim 1, wherein R^2 is $-C(=W)R^6$, (wherein W and R^6 have the same meanings as those mentioned above, respectively).

3. (Currently Amended) The method ~~The mitotic kinesin Eg5 inhibitor~~ according to claim 2, wherein R^6 is a substituted or unsubstituted lower alkyl.

4. (Currently Amended) The method ~~The mitotic kinesin Eg5 inhibitor~~ according to claim 1, wherein R^3 is $-C(=Z)R^{19}$, (wherein Z and R^{19} have the same meanings as those mentioned above, respectively).

5. (Currently Amended) The method ~~The mitotic kinesin Eg5 inhibitor~~ according to claim 4, wherein R^{19} is a substituted or unsubstituted lower alkyl.

6. (Currently Amended) The method ~~The mitotic kinesin Eg5 inhibitor~~ according to claim 1, wherein R^5 is a substituted or unsubstituted aryl, or a substituted or unsubstituted aromatic heterocyclic group.

7. (Currently Amended) The method ~~The mitotic kinesin Eg5 inhibitor~~ according to claim 1, wherein R^5 is a substituted or unsubstituted aryl.

8. (Currently Amended) The method ~~The mitotic kinesin Eg5 inhibitor~~ according to claim 1, wherein R^4 is a substituted or unsubstituted lower alkyl, or $-(CH_2)_nNHSO_2R^{24}$, (wherein n represents 1 or 2, and R^{24} represents a substituted or unsubstituted lower alkyl, a substituted or unsubstituted lower alkenyl, an amino, a lower alkylamino, or a di-(lower alkyl)amino).


9. (Currently Amended) The method ~~The mitotic kinesin Eg5 inhibitor~~ according to claim 1, wherein R^4 and R^5 are combined together to represent $-(CR^{25A}R^{25B})_{m1}Q(CR^{25C}R^{25D})_{m2-1}$ (wherein R^{25A} , R^{25B} , R^{25C} , R^{25D} , $m1$, $m2$, and Q have the same meanings as those mentioned above, respectively).

10. (Currently Amended) The method ~~The mitotic kinesin Eg5 inhibitor~~ according to claim 9, wherein Q is a substituted or unsubstituted phenylene.

11. (Currently Amended) The method ~~The mitotic kinesin Eg5 inhibitor~~ according to claim 1, wherein R^1 is a hydrogen atom.

12. (Currently Amended) The method ~~The mitotic kinesin Eg5 inhibitor~~ according to claim 1, wherein W and Z are oxygen atoms.

13. (Currently Amended) A thiadiazoline derivative represented by the general formula (IA) or a pharmacologically acceptable salt thereof:



wherein R^{1A} represents a hydrogen atom,

R^{2A} represents

a hydrogen atom or

$-COR^{6A}$, (wherein R^{6A} represents a substituted or unsubstituted lower alkyl), or

R^{1A} and R^{2A} are combined together with the adjacent nitrogen atom to form a substituted or unsubstituted heterocyclic group,

R^{3A} represents $-COR^{19A}$, (wherein R^{19A} represents a substituted or unsubstituted lower alkyl),

R^{4A} represents

$-(CH_2)_pNR^{4AA}R^{4AB}$, {wherein

p represents 1 or 2, and

R^{4AA} and R^{4AB} are the same or different and each represents

a hydrogen atom,

a lower alkyl or cycloalkyl, (with the proviso that when R^{2A} is -

COR^{6A} , R^{6A} and R^{19A} are tert-butyl and R^{5A} is phenyl, R^{4AA}

and R^{4AB} are not methyl at the same time}},

$-(CH_2)_pNR^{4AD}COR^{4AC}$, (wherein p has the same meaning as that mentioned

above, R^{4AC} represents a hydrogen atom, a lower alkyl, or a lower alkoxy,

and R^{4AD} represents a hydrogen atom or a lower alkyl), or

$-(CH_2)_pNHSO_2R^{24A}$, {wherein p has the same meaning as that mentioned above,

R^{24A} represents

$-(CH_2)_qNR^{24AA}R^{24AB}$, {wherein q represents an integer of from 0 to 5, and R^{24AA} and R^{24AB} are the same or different and each represents a hydrogen atom, a substituted or unsubstituted lower alkyl or cycloalkyl, {with the proviso that when R^{2A} is $-COR^{6A}$, R^{6A} is tert-butyl and R^{19A} is methyl or tert-butyl, neither of R^{24AA} and R^{24AB} is methyl, and if one of R^{24AA} and R^{24AB} is a hydrogen atom in this case, the other is not ethyl or hydroxyethyl}},

3-chloropropyl,

3-azidopropyl, or

lower alkenyl, {with the proviso that when R^{2A} is $-COR^{6A}$, R^{6A} is tert-butyl and R^{19A} is methyl or tert-butyl, R^{24A} is not vinyl)}, and

R^{5A} represents a substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group>.

14. (Original) The thiadiazoline derivative or a pharmacologically acceptable salt thereof according to claim 13, wherein R^{5A} is substituted or unsubstituted aryl.

15. (Original) The thiadiazoline derivative or a pharmacologically acceptable salt thereof according to claim 13, wherein R^{5A} is phenyl.

16. (Previously Presented) The thiadiazoline derivative or a pharmacologically acceptable salt thereof according to claim 13, wherein R^{2A} is COR^{6A} , and R^{6A} is unsubstituted lower alkyl.

17. (Previously Presented) The thiadiazoline derivative or a pharmacologically acceptable salt thereof according to claim 13, wherein R^{2A} is COR^{6A} , and R^{6A} is tert-butyl.

18. (Previously Presented) The thiadiazoline derivative or a pharmacologically acceptable salt thereof according to claim 13, wherein R^{19A} is unsubstituted lower alkyl.

19. (Previously Presented) The thiadiazoline derivative or a pharmacologically acceptable salt thereof according to claim 13, wherein R^{19A} is tert-butyl.

20. (Currently Amended) The thiadiazoline derivative or a pharmacologically acceptable salt thereof according to claim 13, wherein R^{4A} is $-(CH_2)_pNR^{4AA}R^{4AB}$, (wherein p , R^{4AA} and R^{4AB} have the same meanings as those mentioned above, respectively).

21. (Currently Amended) The thiadiazoline derivative or a pharmacologically acceptable salt thereof according to claim 13, wherein R^{4A} is $-(CH_2)_pR^{4AD}COR^{4AC}$, (wherein p , R^{4AC} and R^{4AD} have the same meanings as those mentioned above, respectively).

22. (Previously Presented) The thiadiazoline derivative or a pharmacologically acceptable salt thereof according to claim 13, wherein R^{4A} is $-(CH_2)_pNHSO_2R^{24A}$, (wherein p and R^{24A} have the same meanings as those mentioned above, respectively).

23. (Previously Presented) A medicament which comprises the thiadiazoline derivative or a pharmacologically acceptable salt thereof according to claim 13 as an active ingredient.

24. (Canceled)

25. (Canceled)

26. (Previously Presented) A method for inhibiting a mitotic kinesin Eg5 which comprises administering an effective amount of the thiadiazoline derivative or a pharmacologically acceptable salt thereof according to claim 13.

27.-28. (Canceled)